{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:22:55Z","timestamp":1774581775334,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti-CD20 therapies have revolutionized the treatment of B-cell malignancies. Despite these advances, relapsed and refractory disease remains a major treatment challenge. The optimization of CD20-targeted immunotherapies is considered a promising strategy to improve current therapies. However, research has been limited by the scarcity of preclinical models that recapitulate the complex interaction between the immune system and cancers. The addition of the canine lymphoma (cNHL) model in the development of anti-CD20 therapies may provide a clinically relevant approach for the translation of improved immunotherapies. Still, an anti-CD20 therapy for cNHL has not been established stressing the need of a comprehensive target characterization. Herein, we performed an in-depth characterization on canine CD20 mRNA transcript and protein expression in a cNHL biobank and demonstrated a canine CD20 overexpression in B-cell lymphoma samples. Moreover, CD20 gene sequencing analysis identified six amino acid differences in patient samples (C77Y, L147F, I159M, L198V, A201T and G273E). Finally, we reported the use of a novel strategy for the generation of anti-CD20 mAbs, with human and canine cross-reactivity, by exploring our rabbit derived single-domain antibody platform. Overall, these results support the rationale of using CD20 as a target for veterinary settings and the development of novel therapeutics and immunodiagnostics.<\/jats:p>","DOI":"10.1038\/s41598-022-06549-1","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:02:53Z","timestamp":1645095773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Joana N. R.","family":"Dias","sequence":"first","affiliation":[]},{"given":"Andr\u00e9","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Ana S.","family":"Andr\u00e9","sequence":"additional","affiliation":[]},{"given":"Sandra I.","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Bule","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Soraia S.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Belmira","family":"Carrapi\u00e7o","sequence":"additional","affiliation":[]},{"given":"Solange","family":"Gil","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Tavares","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-419X","authenticated-orcid":false,"given":"Frederico","family":"Aires-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"6549_CR1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"6549_CR2","doi-asserted-by":"publisher","DOI":"10.1211\/PJ.2020.20207825","author":"S Carter","year":"2020","unstructured":"Carter, S. & Thurston, D. E. Immuno-oncology agents for cancer therapy. Pharm. J. https:\/\/doi.org\/10.1211\/PJ.2020.20207825 (2020).","journal-title":"Pharm. J."},{"key":"6549_CR3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/17460441.2015.1045295","volume":"10","author":"P Smolewski","year":"2015","unstructured":"Smolewski, P. & Robak, T. The preclinical discovery of rituximab for the treatment of non-Hodgkin\u2019s lymphoma. Expert Opin. Drug Discov. 10, 791\u2013808 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"6549_CR4","first-page":"1","volume":"8","author":"TM Pierpont","year":"2015","unstructured":"Pierpont, T. M., Limper, C. B. & Richards, K. L. Past, present, and future of rituximab\u2014The world\u2019s first oncology monoclonal antibody therapy. Front. Oncol. 8, 1\u201323 (2018).","journal-title":"Front. Oncol."},{"key":"6549_CR5","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan, J. M. L., Wong, J., Northcott, M. J. & Opat, S. Anti-CD20 monoclonal antibodies: Reviewing a revolution. Hum. Vaccines Immunother. 14, 2820\u20132841 (2018).","journal-title":"Hum. Vaccines Immunother."},{"key":"6549_CR6","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","volume":"11","author":"C Luo","year":"2021","unstructured":"Luo, C. et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20 + B-cell non-Hodgkin lymphomas: A systematic review and meta-analysis. Sci. Rep. 11, 3255 (2021).","journal-title":"Sci. Rep."},{"key":"6549_CR7","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2017.01936","volume":"8","author":"C Cuesta-Mateos","year":"2018","unstructured":"Cuesta-Mateos, C., Alcaraz-Serna, A., Somovilla-Crespo, B. & Mu\u00f1oz-Calleja, C. Monoclonal antibody therapies for hematological malignancies: Not just lineage-specific targets. Front. Immunol. 8, 1936 (2018).","journal-title":"Front. Immunol."},{"key":"6549_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","volume":"9","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan, H. M. et al. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 9, 10\u201325 (2009).","journal-title":"Int. Immunopharmacol."},{"key":"6549_CR9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","volume":"4","author":"HL Gardner","year":"2016","unstructured":"Gardner, H. L., Fenger, J. M. & London, C. A. Dogs as a model for cancer. Annu. Rev. Anim. Biosci. 4, 199\u2013222 (2016).","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"6549_CR10","first-page":"165","volume":"159","author":"SS Pinho","year":"2012","unstructured":"Pinho, S. S., Carvalho, S., Cabral, J., Reis, C. A. & G\u00e4rtner, F. Canine tumors: A spontaneous animal model of human carcinogenesis. Transl. Res. J. Lab. Clin. Med. 159, 165\u2013172 (2012).","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"6549_CR11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nbt0906-1065b","volume":"24","author":"C Khanna","year":"2006","unstructured":"Khanna, C. et al. The dog as a cancer model. Nat. Biotechnol. 24, 1065\u20131066 (2006).","journal-title":"Nat. Biotechnol."},{"key":"6549_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2017","volume":"31","author":"L Marconato","year":"2013","unstructured":"Marconato, L., Gelain, M. E. & Comazzi, S. The dog as a possible animal model for human non-Hodgkin lymphoma: A review. Hematol. Oncol. 31, 1\u20139 (2013).","journal-title":"Hematol. Oncol."},{"key":"6549_CR13","doi-asserted-by":"crossref","unstructured":"Vail, D. M., Young, K. M., & Pinkerton, M. E. Chapter 31\u2014Hematopoietic tumors. In Withrow & MacEwen\u2019s Small Animal Clinical Oncology, 4th ed. (eds. Withrow, S. J., Vail, D. M., & Page, L. R.) 699\u2013784 (W.B. Saunders, 2007).","DOI":"10.1016\/B978-072160558-6.50034-4"},{"key":"6549_CR14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/01652176.2016.1152633","volume":"36","author":"M Zandvliet","year":"2016","unstructured":"Zandvliet, M. Canine lymphoma: A review. Vet. Q. 36, 76\u2013104 (2016).","journal-title":"Vet. Q."},{"key":"6549_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/vco.12253","volume":"14","author":"D Argyle","year":"2016","unstructured":"Argyle, D. & Pecceu, E. Canine and feline lymphoma: Challenges and opportunities for creating a paradigm shift. Vet. Comp. Oncol. 14, 1\u20137 (2016).","journal-title":"Vet. Comp. Oncol."},{"key":"6549_CR16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1354\/vp.42-4-468","volume":"42","author":"CM Jubala","year":"2005","unstructured":"Jubala, C. M. et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet. Pathol. 42, 468\u2013476 (2005).","journal-title":"Vet. Pathol."},{"key":"6549_CR17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.vetimm.2005.05.011","volume":"108","author":"R Kano","year":"2005","unstructured":"Kano, R. et al. Canine CD20 gene. Vet. Immunol. Immunopathol. 108, 265\u2013268 (2005).","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"171","key":"6549_CR18","first-page":"556","volume":"1997","author":"JA Impellizeri","year":"2006","unstructured":"Impellizeri, J. A., Howell, K., McKeever, K. P. & Crow, S. E. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. Vet. J. Lond. Engl. 1997(171), 556\u2013558 (2006).","journal-title":"Vet. J. Lond. Engl."},{"key":"6549_CR19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/10428194.2014.914193","volume":"56","author":"D Ito","year":"2015","unstructured":"Ito, D., Brewer, S., Modiano, J. F. & Beall, M. J. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk. Lymphoma 56, 219\u2013225 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"6549_CR20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vetimm.2015.02.004","volume":"164","author":"SM Rue","year":"2015","unstructured":"Rue, S. M. et al. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Vet. Immunol. Immunopathol. 164, 148\u2013159 (2015).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"6549_CR21","volume":"11","author":"S Jain","year":"2016","unstructured":"Jain, S. et al. The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine. PLoS\u00a0One 11, e0148366 (2016).","journal-title":"PLoS\u00a0One"},{"key":"6549_CR22","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1038\/s41598-020-68470-9","volume":"10","author":"T Mizuno","year":"2020","unstructured":"Mizuno, T. et al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci. Rep. 10, 11476 (2020).","journal-title":"Sci. Rep."},{"key":"6549_CR23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1746-1596-6-33","volume":"6","author":"VK Prevodnik","year":"2011","unstructured":"Prevodnik, V. K., Lavren\u010dak, J., Horvat, M. & Novakovi\u010d, B. J. The predictive significance of CD20 expression in B-cell lymphomas. Diagn. Pathol. 6, 33 (2011).","journal-title":"Diagn. Pathol."},{"key":"6549_CR24","doi-asserted-by":"crossref","first-page":"109940","DOI":"10.1016\/j.vetimm.2019.109940","volume":"218","author":"JNR Dias","year":"2019","unstructured":"Dias, J. N. R. et al. Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation. Vet. Immunol. Immunopathol. 218, 109940 (2019).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"6549_CR25","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4049\/jimmunol.142.7.2555","volume":"142","author":"TF Tedder","year":"1989","unstructured":"Tedder, T. F. et al. The gene that encodes the human CD20 (B1) differentiation antigen is located on chromosome 11 near the t(11;14)(q13;q32) translocation site. J. Immunol. 142, 2555\u20132559 (1989).","journal-title":"J. Immunol."},{"key":"6549_CR26","first-page":"17","volume":"27","author":"JK Riley","year":"2000","unstructured":"Riley, J. K. & Sliwkowski, M. X. CD20: A gene in search of a function. Semin. Oncol. 27, 17\u201324 (2000).","journal-title":"Semin. Oncol."},{"key":"6549_CR27","doi-asserted-by":"crossref","unstructured":"Beall, M. & Elizabeth, C. Canine CD20 compositions. U.S. Application 60\/575,172 (2005).","DOI":"10.1093\/acprof:oso\/9780199288403.003.0006"},{"key":"6549_CR28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","volume":"34","author":"BC R\u00fctgen","year":"2010","unstructured":"R\u00fctgen, B. C. et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk. Res. 34, 932\u2013938 (2010).","journal-title":"Leuk. Res."},{"key":"6549_CR29","unstructured":"Goncalves J.M.B., Da Silva F.N.C.A. Engineered rabbit antibody variable domains and uses thereof. International Patent Application. No. PCT\/PT2008\/000018. WO2008136694A9 (2008)."},{"key":"6549_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.dci.2005.06.017","volume":"30","author":"RG Mage","year":"2006","unstructured":"Mage, R. G., Lanning, D. & Knight, K. L. B cell and antibody repertoire development in rabbits: The requirement of gut-associated lymphoid tissues. Dev. Comp. Immunol. 30, 137\u2013153 (2006).","journal-title":"Dev. Comp. Immunol."},{"key":"6549_CR31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.gene.2003.12.037","volume":"330","author":"F Ros","year":"2004","unstructured":"Ros, F. et al. Sequence analysis of 0.5 Mb of the rabbit germline immunoglobulin heavy chain locus. Gene 330, 49\u201359 (2004).","journal-title":"Gene"},{"key":"6549_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s002510050683","volume":"50","author":"D Sehgal","year":"1999","unstructured":"Sehgal, D., Johnson, G., Wu, T. T. & Mage, R. G. Generation of the primary antibody repertoire in rabbits: Expression of a diverse set of Igk-V genes may compensate for limited combinatorial diversity at the heavy chain locus. Immunogenetics 50, 31\u201342 (1999).","journal-title":"Immunogenetics"},{"key":"6549_CR33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2017.00494","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z., Liu, H., Guan, Q., Wang, L. & Yuan, H. Advances in the isolation of specific monoclonal rabbit antibodies. Front. Immunol. 8, 494 (2017).","journal-title":"Front. Immunol."},{"key":"6549_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jim.2004.05.004","volume":"291","author":"M Popkov","year":"2004","unstructured":"Popkov, M., Rader, C. & Barbas, C. F. Isolation of human prostate cancer cell reactive antibodies using phage display technology. J. Immunol. Methods 291, 137\u2013151 (2004).","journal-title":"J. Immunol. Methods"},{"key":"6549_CR35","first-page":"278","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott, A. M., Allison, J. P. & Wolchok, J. D. Monoclonal antibodies in cancer therapy. Cancer Immun. 12, 278\u2013287 (2012).","journal-title":"Cancer Immun."},{"key":"6549_CR36","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-11-1429","volume":"18","author":"P-C Tsai","year":"2012","unstructured":"Tsai, P.-C., Hernandez-Ilizaliturri, F. J., Bangia, N., Olejniczak, S. H. & Czuczman, M. S. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18, 1039\u20131050 (2012).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"6549_CR37","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825\u20132833 (1998).","journal-title":"J. Clin. Oncol."},{"key":"6549_CR38","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis, T. A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: Safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135\u20133143 (2000).","journal-title":"J. Clin. Oncol."},{"key":"6549_CR39","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","volume":"12","author":"T van Meerten","year":"2006","unstructured":"van Meerten, T., van Rijn, R. S., Hol, S., Hagenbeek, A. & Ebeling, S. B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12, 4027\u20134035 (2006).","journal-title":"Clin. Cancer Res."},{"key":"6549_CR40","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.31","volume":"1","author":"GW Small","year":"2013","unstructured":"Small, G. W., McLeod, H. L. & Richards, K. L. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ 1, e31 (2013).","journal-title":"PeerJ"},{"key":"6549_CR41","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman, M. S. et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 14, 1561\u20131570 (2008).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"6549_CR42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4049\/jimmunol.182.1.416","volume":"182","author":"F Perosa","year":"2009","unstructured":"Perosa, F. et al. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J. Immunol. 182, 416\u2013423 (2009).","journal-title":"J. Immunol."},{"key":"6549_CR43","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","volume":"12","author":"C Henry","year":"2010","unstructured":"Henry, C. et al. Identification of an alternative CD20 transcript variant in B cell malignancies coding for a novel protein associated to rituximab resistance. Blood 12, 2420\u20132429 (2010).","journal-title":"Blood"},{"key":"6549_CR44","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Roug\u00e9","year":"2020","unstructured":"Roug\u00e9, L. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367, 1224\u20131230 (2020).","journal-title":"Science"},{"key":"6549_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein, C. et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5, 22\u201333 (2013).","journal-title":"MAbs"},{"key":"6549_CR46","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V99.9.3256","volume":"99","author":"MJ Polyak","year":"2002","unstructured":"Polyak, M. J. & Deans, J. P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99, 3256\u20133262 (2002).","journal-title":"Blood"},{"key":"6549_CR47","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.4049\/jimmunol.161.7.3242","volume":"161","author":"MJ Polyak","year":"1998","unstructured":"Polyak, M. J., Tailor, S. H. & Deans, J. P. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J. Immunol. 161, 3242\u20133248 (1998).","journal-title":"J. Immunol."},{"key":"6549_CR48","doi-asserted-by":"crossref","first-page":"15150","DOI":"10.1021\/bi0511078","volume":"44","author":"JA Ernst","year":"2005","unstructured":"Ernst, J. A. et al. Isolation and characterization of the B-cell marker CD20. Biochemistry 44, 15150\u201315158 (2005).","journal-title":"Biochemistry"},{"key":"6549_CR49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/vetsci2040363","volume":"2","author":"KL Anderson","year":"2015","unstructured":"Anderson, K. L. & Modiano, J. F. Progress in adaptive immunotherapy for cancer in companion animals: Success on the path to a cure. Vet. Sci. 2, 363\u2013387 (2015).","journal-title":"Vet. Sci."},{"key":"6549_CR50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jsap.12336","volume":"56","author":"DR Killick","year":"2015","unstructured":"Killick, D. R., Stell, A. J. & Catchpole, B. Immunotherapy for canine cancer\u2014Is it time to go back to the future?. J. Small Anim. Pract. 56, 229\u2013241 (2015).","journal-title":"J. Small Anim. Pract."},{"key":"6549_CR51","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1074\/jbc.275.18.13668","volume":"275","author":"C Rader","year":"2000","unstructured":"Rader, C. et al. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J. Biol. Chem. 275, 13668\u201313676 (2000).","journal-title":"J. Biol. Chem."},{"key":"6549_CR52","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.23","volume":"49","author":"J Weber","year":"2017","unstructured":"Weber, J., Peng, H. & Rader, C. From rabbit antibody repertoires to rabbit monoclonal antibodies. Exp. Mol. Med. 49, e305 (2017).","journal-title":"Exp. Mol. Med."},{"key":"6549_CR53","first-page":"301","volume":"22","author":"F Aires da Silva","year":"2008","unstructured":"Aires da Silva, F., Corte-Real, S. & Goncalves, J. Recombinant antibodies as therapeutic agents: Pathways for modeling new biodrugs. BioDrugs Clin. Immunother. Biopharm. Gene Ther. 22, 301\u2013314 (2008).","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"6549_CR54","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.3390\/ijms13055420","volume":"13","author":"C Dantas-Barbosa","year":"2012","unstructured":"Dantas-Barbosa, C., de Macedo Brigido, M. & Maranhao, A. Q. Antibody phage display libraries: Contributions to oncology. Int. J. Mol. Sci. 13, 5420\u20135440 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"6549_CR55","unstructured":"Owen, L. N. TNM Classification of Tumours in Domestic Animal. World Health Organization. 1\u201353 (1980)."},{"key":"6549_CR56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 25, 402\u2013408 (2001).","journal-title":"Methods San Diego Calif."},{"key":"6549_CR57","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.1067081","volume":"295","author":"C Lois","year":"2002","unstructured":"Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868\u2013872 (2002).","journal-title":"Science"},{"key":"6549_CR58","unstructured":"Dias, J. N. R. Clinical and Immunological Characterization of Naturally Occurring Canine Lymphoma: Development and Application of Engineered Recombinant Antibodies for Diagnosis and Treatment. (University of Lisbon, 2019)."},{"key":"6549_CR59","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3390\/pharmaceutics13101598","volume":"13","author":"SI Aguiar","year":"2021","unstructured":"Aguiar, S. I. et al. Highly specific blood\u2013brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening. Pharmaceutics 13, 1598 (2021).","journal-title":"Pharmaceutics"},{"key":"6549_CR60","doi-asserted-by":"crossref","first-page":"7978","DOI":"10.1073\/pnas.88.18.7978","volume":"88","author":"CF Barbas","year":"1991","unstructured":"Barbas, C. F., Kang, A. S., Lerner, R. A. & Benkovic, S. J. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. U. S. A. 88, 7978\u20137982 (1991).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06549-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T06:55:04Z","timestamp":1674802504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06549-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2678"}}